Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Hong, DS; Schoffski, P; Calvo, A; Sarantopoulos, J; Ochoa De Olza, M; Carvajal, RD; Prawira, A; Kyi, C; Esaki, T; Akerley, WL; De Braud, FG; Hui, R; Zhang, T; Soo, RA; Maur, M; Weickhardt, AJ; Roy Chowdhury, N; Sabatos-Peyton, C; Kwak, EL; Tan, DS-W

Published Date

  • May 20, 2018

Published In

Volume / Issue

  • 36 / 15_suppl

Start / End Page

  • 3012 - 3012

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.15_suppl.3012